Back to today’s briefing

Story perspectives

Merck Battles Patent Dispute While Adapting Keytruda

3/5/2025

49 3

Summary

Story summary

Merck is adapting Keytruda to maintain revenue as U.S. patent protection ends in 2028.
A patent dispute with Halozyme Therapeutics could impact Merck's new injected Keytruda.
Halozyme alleges patent infringement, while Merck contests this and aims to invalidate the patents.
Clinical testing for the injected Keytruda is underway, with a projected launch in early 2026.

1 of 1

Story summary

Merck is adapting Keytruda to maintain revenue as U.S. patent protection ends in 2028.
A patent dispute with Halozyme Therapeutics could impact Merck's new injected Keytruda.
Halozyme alleges patent infringement, while Merck contests this and aims to invalidate the patents.
Clinical testing for the injected Keytruda is underway, with a projected launch in early 2026.